Maat Pharma S.a. Stock
Price
Target price
€8.84
€8.84
-0.670%
-0.06
-0.670%
€10.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Maat Pharma S.a. Stock
The price for the Maat Pharma S.a. stock decreased slightly today. Compared to yesterday there is a change of -€0.060 (-0.670%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Maat Pharma S.a. stock is not clear.
As a result the target price of 10 € shows a slightly positive potential of 13.12% compared to the current price of 8.84 € for Maat Pharma S.a..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Maat Pharma S.a. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Maat Pharma S.a. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to